Latest News
Callaway Gains After Cutting Ties with Good Good, Commits $1M
Callaway shares climbed 2.5% after terminating its Good Good Golf partnership and pledging $1 million to anti-violence groups, a move analysts see as a brand-risk reset.
Novavax Dips Slightly After Nuvaxovid Gains Approval in US, EU, Japan
Novavax shares slipped 0.6% to $9.00 after regulatory approvals for its updated vaccine in the US, EU, and Japan. The company now relies on partners like Sanofi for commercialization, with royalties expected but not yet in guidance.
Synopsys Stock Retreats 3.4% as Investors Digest Ansys Integration Costs
Synopsys shares dropped 3.4% Friday, wiping out $3.1 billion in market cap, as investors weighed record Q3 revenue and Ansys integration costs.
FingerMotion Soars 262% on AI Data-Center Plan
FingerMotion shares jumped 261.7% to $0.6272 after unveiling a modular AI data-center plan with BlueFlare Energy Solutions, targeting Western Canada. The stock surged on heavy volume, but no definitive agreements are in place.
Sibanye-Stillwater Soars 216% on H1 Profit Surge
Sibanye-Stillwater ADRs climbed 1.6% after the miner forecast a 216% jump in first-half headline earnings per share, driven by surging gold and platinum-group-metal prices.
N-able Surges 9% on $95M Buyback Boost
N-able (NABL) shares jumped 9% after increasing its share repurchase authorization to $95 million, equal to 11.7% of its market value.
SharonAI Tumbles 4.2% as Nvidia Pauses Cloud Financing, Clouding $4.88B Deal
SharonAI shares dropped 4.2% after Nvidia paused parts of a cloud financing initiative, raising questions about its $4.88 billion compute agreement.
Workday Rallies 2.9% as AI Agents Drive Over 25% of New Contract Value
Workday (WDAY) shares climbed 2.9% as AI agents contributed over 25% of new contract value. Subscription revenue grew 13.9%, but free cash flow declined.
Veeva Stock Holds Gains as Q2 Earnings, Margins Impress
Veeva shares hold 14.8% gain post-earnings as Q2 revenue jumps 18% to $928M, with operating margin expanding 480 bps and AI-driven demand. FY guidance raised.
Cytokinetics Drops 5% Despite Positive Phase 3 Data in nHCM
Cytokinetics shares slid 5% despite positive Phase 3 trial results for MYQORZO in non-obstructive HCM, as investors hoped for larger clinical benefits.
BioNTech Slumps 6.6% as Colorectal Cancer Vaccine Trial Halted
BioNTech shares dropped 6.6% after the company ended a Phase 2 trial of its colorectal cancer vaccine. The decision follows a data safety board recommendation and erases about $1.8 billion in market value.
Moderna Drops 3.4% on $2.6B Convertible Offering Amid Cancer Vaccine Rally
Moderna shares slid 3.4% to $137.86 after pricing a $2.6B zero-coupon convertible notes offering, sparking dilution worries and cooling the recent cancer-vaccine rally.